46
Participants
Start Date
May 1, 2022
Primary Completion Date
November 10, 2023
Study Completion Date
December 30, 2023
Control group (clozapine, placebo)
Patients received oral clozapine (Jiangsu Pharmaceutical Co., Ltd., Approval No. H32022963) in combination with a placebo. Each dose of the placebo was 1 mg, taken three times a day.
Low-dose group (buspirone tablets, clozapine)
Patients received oral buspirone tablets (Jiangsu Enhua Pharmaceutical Co., Ltd., Approval No. H19991024) in combination with clozapine. The total daily dose of buspirone was 15 mg, divided into three administrations. The dose remained unchanged throughout the entire study period.
High-dose group (buspirone tablets, clozapine)
Patients received oral buspirone tablets in combination with clozapine. The initial total daily dose of buspirone was 15 mg, divided into three administrations. One week later, the dose was increased to a total daily dose of 30 mg, also divided into three administrations.
Wuhu Fourth People's Hospital affiliated with Bengbu Medical University, Wuhu
Wuhu Fourth People's Hospital affiliated with Bengbu Medical University
OTHER
Chuanfu Song
OTHER